$MDT · Medtronic plc

Medtronic filed an 8-K disclosing two events: (1) the appointment of Michael Marinaro as President, Medtronic, effective October 14, 2026, with expanded oversight of Greater China operations alongside his existing Medical Surgical Portfolio and Global Commercial Operations role; and (2) the completion of the MiniMed Group separation via an exchange offer that was 5.4x subscribed, with Medtronic exchanging all 252,813,348 remaining MiniMed shares.

Extended-hours trading shows MDT at $92.47, down 0.32% from the regular-session close of $92.77. The modest after-hours dip suggests the MiniMed separation completion and President appointment were largely anticipated events on a $118.67B market cap.

The MiniMed separation closes a major strategic restructuring for the $118.67B medtech giant, while the President appointment signals a succession-ready leadership bench under CEO Geoff Martha.

The MiniMed spin-off completes Medtronic's exit from the diabetes device market, sharpening focus on Cardiovascular, Neuroscience, and Surgical portfolios — a trend of medtech conglomerates streamlining to unlock shareholder value.

Forward-looking statement cautions include risks around realizing anticipated separation benefits, MiniMed's ability to succeed as an independent public company, and whether the transaction qualifies as generally tax-free for U.S. federal income tax purposes.